Clinical features of recurrent ovarian carcinoma and prognosis comparison of different treatment
Juan NI,Yaxia CHEN
DOI: https://doi.org/10.13558/j.cnki.issn1672-3686.2014.01.043
2014-01-01
Abstract:Objective To investigate the clinical features of recurrent ovarian carcinoma and the effects of two different treatments on prognosis and explore the factors that can prolong the disease-free interval(DFI). Methods Fifty-four cases of recurrent ovarian carcinoma with completed clinical therapy data were collected and retrospectively reviewed. The rela-tionship between DFI and total survival time, possible factors including pathologic type, clinical stage, residual mass, and chemotherapy course were analyzed. The re-remission rate and survival time between different treatments of recurrent ovar-ian carcinoma were compared. Results In 39 death cases, the longer the DFI after initial treatment, the longer the pa-tients' survival time, there was a positive correlation between them (r=0.65, P<0.05). The DFI of different pathological types of ovarian carcinoma were different(F=6.22,P<0.05).There was no significant difference of DFI between serous car-cinoma and endometrial carcinoma (q=0.52,P>0.05). Compared with serous carcinoma and endometrial carcinoma, the DFI of adenocarcinoma was significantly shorter (q=0.03,0.01,P<0.05).Early staging, small residual mass and standard-ized chemotherapy courses could prolong DFI (t=2.29,2.99,2.24,P<0.05). Compared with remedial chemotherapy, pa-tients underwent secondary cytoreductive surgery followed with remedial chemotherapy had higher re-remission rate (χ2=16.27,P<0.05).There were a significant differences in 2 and 3 years survival rates between the patients received two types of therapy (χ2=11.20,11.84,P<0.05)while there were no significant differences in 1, 4 and 5 years survival rates (χ2=5.59,6.42,4.38,P>0.05). Conclusions Pathologic type, clinical stage, residual mass and chemotherapy course have some effects on the DFI. Secondary cytoreductive surgery with chemotherapy can improve the short-term survival rate of recurrent ovarian carcinoma, but it can not prolong the patients'survival time.